Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor ...

SGLT2 inhibitors are already used to treat diabetes and chronic kidney disease. This study helps explain why patients taking ...

A new study examines how a diabetes drug may protect the kidneys from aging.

In patients with diabetes, sustained use of GLP-1 receptor agonists is associated with a modestly higher risk for new-onset ...

SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the clinical impact.

MADRID — Nearly half of people with type 2 diabetes (T2D) currently recommended to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney protection would not actually benefit from them, ...

A new study published in the Journal of American Medical Association showed that when renal protection is a primary therapeutic objective, starting treatment with an SGLT2 inhibitor (SGLT2i) ...

Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...

Credit: Getty Images Researchers compared rates of gout medication initiation among patients with gout and type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists. The use of ...